miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker

In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases t...

Full description

Bibliographic Details
Main Authors: Arulraj Nadaradjane, Joséphine Briand, Gwenola Bougras-Cartron, Valentine Disdero, François M. Vallette, Jean-Sébastien Frenel, Pierre-François Cartron
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:Molecular Therapy: Nucleic Acids
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253118302518
_version_ 1818261001050521600
author Arulraj Nadaradjane
Joséphine Briand
Gwenola Bougras-Cartron
Valentine Disdero
François M. Vallette
Jean-Sébastien Frenel
Pierre-François Cartron
author_facet Arulraj Nadaradjane
Joséphine Briand
Gwenola Bougras-Cartron
Valentine Disdero
François M. Vallette
Jean-Sébastien Frenel
Pierre-François Cartron
author_sort Arulraj Nadaradjane
collection DOAJ
description In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the “Prognostic miRNA Database” indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. A second approach quantifying the expression level of cell-free circulating miRNA-370-3p (cfc-miR-370-3p) also indicated that cfc-miR-370-3p is not associated with a prognosis value for survival. To investigate whether miR-370-3p can be used in vivo to increase the anti-GBM effect of TMZ, we then used the model of LN18-induced GBMs in mice. Our data indicated that the miRNA-370-3p/TMZ treatment was two times more efficient than the TMZ treatment for decreasing the tumor volume. In addition, our study correlated the decrease of tumor volume induced by the miRNA-370-3p/TMZ treatment with the decrease in FOXM1 and MGMT (i.e., two targets of miR-370-3p).Our data thus support the idea that miR-370-3p could be used as therapeutic tool for anti-glioblastoma therapy, but not as a biomarker. Keywords: GBM, miRNA, temozolomide
first_indexed 2024-12-12T18:40:17Z
format Article
id doaj.art-7362bc54b37f4aadb1a5de236436990f
institution Directory Open Access Journal
issn 2162-2531
language English
last_indexed 2024-12-12T18:40:17Z
publishDate 2018-12-01
publisher Elsevier
record_format Article
series Molecular Therapy: Nucleic Acids
spelling doaj.art-7362bc54b37f4aadb1a5de236436990f2022-12-22T00:15:41ZengElsevierMolecular Therapy: Nucleic Acids2162-25312018-12-0113642650miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating BiomarkerArulraj Nadaradjane0Joséphine Briand1Gwenola Bougras-Cartron2Valentine Disdero3François M. Vallette4Jean-Sébastien Frenel5Pierre-François Cartron6Equipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, FranceDepartment of Medical Oncology, Institut de Cancérologie de l’Ouest site René Gauducheau, Saint Herblain, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, France; LabEX IGO, Université de Nantes, Nantes, FranceDepartment of Medical Oncology, Institut de Cancérologie de l’Ouest site René Gauducheau, Saint Herblain, FranceEquipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France; Faculté de Médecine, Université de Nantes, Nantes, France; LaBCT, Institut de Cancérologie de l’Ouest, Saint Herblain, France; Cancéropole Grand-Ouest, réseau Epigénétique (RepiCGO), Université de Nantes, Nantes, France; EpiSAVMEN Consortium (Région Pays de la Loire), Université de Nantes, Nantes, France; LabEX IGO, Université de Nantes, Nantes, France; Corresponding author: Pierre-François Cartron, Equipe Apoptose & Progression Tumorale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA), INSERM U1232, Nantes, France.In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p can be used as a therapeutic tool that increases the efficiency of standard anti-GBM treatment. A first approach using the data available on the “Prognostic miRNA Database” indicated that the expression level of miRNA-370-3p in GBM (T-miR-370-3p) is not associated with a prognosis value for survival. A second approach quantifying the expression level of cell-free circulating miRNA-370-3p (cfc-miR-370-3p) also indicated that cfc-miR-370-3p is not associated with a prognosis value for survival. To investigate whether miR-370-3p can be used in vivo to increase the anti-GBM effect of TMZ, we then used the model of LN18-induced GBMs in mice. Our data indicated that the miRNA-370-3p/TMZ treatment was two times more efficient than the TMZ treatment for decreasing the tumor volume. In addition, our study correlated the decrease of tumor volume induced by the miRNA-370-3p/TMZ treatment with the decrease in FOXM1 and MGMT (i.e., two targets of miR-370-3p).Our data thus support the idea that miR-370-3p could be used as therapeutic tool for anti-glioblastoma therapy, but not as a biomarker. Keywords: GBM, miRNA, temozolomidehttp://www.sciencedirect.com/science/article/pii/S2162253118302518
spellingShingle Arulraj Nadaradjane
Joséphine Briand
Gwenola Bougras-Cartron
Valentine Disdero
François M. Vallette
Jean-Sébastien Frenel
Pierre-François Cartron
miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
Molecular Therapy: Nucleic Acids
title miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
title_full miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
title_fullStr miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
title_full_unstemmed miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
title_short miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker
title_sort mir 370 3p is a therapeutic tool in anti glioblastoma therapy but is not an intratumoral or cell free circulating biomarker
url http://www.sciencedirect.com/science/article/pii/S2162253118302518
work_keys_str_mv AT arulrajnadaradjane mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker
AT josephinebriand mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker
AT gwenolabougrascartron mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker
AT valentinedisdero mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker
AT francoismvallette mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker
AT jeansebastienfrenel mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker
AT pierrefrancoiscartron mir3703pisatherapeutictoolinantiglioblastomatherapybutisnotanintratumoralorcellfreecirculatingbiomarker